vedolizumab (Entyvio®)

OFFICE ADMINISTRATION

Indications for Prior Authorization:

  • Crohn’s disease
  • Ulcerative colitis

Patients must meet the following criteria for the indications above:

  • Diagnosis of Ulcerative Colitis or Crohn`s Disease AND
  • Diagnosis confirmed by a gastroenterologist
    • Differential diagnosis made to rule out ischemic bowel disease, other inflammatory diseases, or irritable bowel disease
    • Diagnosis confirmed with radiography, endoscopy, and/or capsule endoscopy
    • Patient does not have perforation, abscess, or obstruction
  • For Induction:
    • Patient is not in remission AND
    •  Failure or clinically significant adverse effects to Humira® and Remicade® for Crohn's
    •  Failure or clinically significant adverse effects to Humira® and Remicade® for ulcerative colitis
  •  For Reauthorization:
    • Twelve-week Review: Chart notes documenting benefit of induction therapy. AND
    • Six-Month Review: Chart notes documenting benefit of maintenance and patient is not on oral maintenance steroids

Coverage is Not Authorized For:

  • Non-FDA approved indications, which are not listed in the WHA Approved Indications and Usage Guidelines section, unless there is sufficient documentation of efficacy and safety in the published literature
  • Combination therapy with TNF antagonists [eg. Humira®, Cimzia®, Simponi®, Remicade
  • Combination therapy with Tysabri®
  • Patients who have or have had progressive multifocal leukoencephalopathy (PML)

Dosing:

  • Induction: 300 mg IV at weeks 0, 2 and 6
  • Maintenance Beginning week 14, 300 mg IV q 8 weeks

 

Last review date: July 20, 2016

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.

Press Esc to cancel

El sitio Web al que está siendo transferido no es provisto por WHA. Las Condiciones de Uso y las Prácticas de Privacidad en Internet de WHA no se aplican a este sitio Web asociado que usted está usando. Revise las políticas sobre la privacidad y condiciones de uso de este sitio Web asociado. WHA no tiene control sobre la exactitud, la totalidad o la actualidad del contenido del sitio Web asociado. WHA no puede garantizar que los servicios de traducción de idiomas estarán disponibles en el sitio vinculado.

Presione «Esc» para cancelar